• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组织抗 TNF 药物水平与炎症性肠病的血清学和内镜疾病活动的相关性:ATLAS 研究。

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study.

机构信息

Division of Gastroenterology, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA.

Prometheus Laboratories, San Diego, California, USA.

出版信息

Gut. 2016 Feb;65(2):249-55. doi: 10.1136/gutjnl-2014-308099. Epub 2015 Feb 10.

DOI:10.1136/gutjnl-2014-308099
PMID:25670812
Abstract

OBJECTIVE

The aim of this study was to assess the correlation between serum and intestinal anti-tumour necrosis factor (TNF) levels, and their relationship to endoscopic disease activity and levels of TNF.

DESIGN

Cross-sectional study of 30 patients receiving treatment with infliximab or adalimumab for Crohn's disease or UC. For each patient, a sample of serum was matched to tissue biopsies. Endoscopic and histological disease activity was recorded for each tissue sample.

RESULTS

There was a significant positive correlation between anti-TNF in serum and tissue (r=0.3920, p=0.002), especially in uninflamed tissue (r=0.50, p<0.001), but not with those samples that had inflammation (r=0.19, p=0.54). Anti-TNF concentration in tissue correlated with degree of endoscopic inflammation, except for tissue with severe inflammation in which anti-TNF levels were again lower (mean normalised anti-TNF in tissue: uninflamed=0.93, mild=2.17, moderate=13.71, severe=2.2 inflammation (p=0.0042)). The ratio of anti-TNF-to-TNF in tissue was highest in uninflamed areas and lowest in severely inflamed areas. Patients with active mucosal disease had a higher rate of serum to tissue drug level mismatch when compared to those in remission (73.3% vs 33.3%, respectively; p=0.03).

CONCLUSIONS

Our data suggest that local tissue inflammation characterised by high levels of TNF serves as a sink for anti-TNF. We further postulate that some patients with high serum anti-TNF levels have active disease because tissue levels of anti-TNF are insufficient to neutralise local TNF production.

摘要

目的

本研究旨在评估血清和肠道抗肿瘤坏死因子(TNF)水平之间的相关性,及其与内镜疾病活动度和 TNF 水平的关系。

设计

30 例接受英夫利昔单抗或阿达木单抗治疗的克罗恩病或溃疡性结肠炎患者的横断面研究。为每位患者采集血清样本与组织活检相匹配。记录每个组织样本的内镜和组织学疾病活动度。

结果

血清和组织中的抗 TNF 之间存在显著正相关(r=0.3920,p=0.002),尤其是在无炎症组织中(r=0.50,p<0.001),但与有炎症的组织样本无关(r=0.19,p=0.54)。组织中抗 TNF 浓度与内镜炎症程度相关,但严重炎症组织中的抗 TNF 水平再次较低(组织中正常化抗 TNF 的平均浓度:无炎症=0.93,轻度=2.17,中度=13.71,严重=2.2 炎症(p=0.0042))。组织中抗 TNF 与 TNF 的比值在无炎症区域最高,在严重炎症区域最低。与缓解期患者相比,有活动性黏膜疾病的患者血清与组织药物水平不匹配的发生率更高(分别为 73.3%和 33.3%;p=0.03)。

结论

我们的数据表明,以高 TNF 水平为特征的局部组织炎症充当了抗 TNF 的汇流点。我们进一步假设,一些血清抗 TNF 水平较高的患者患有活动期疾病,因为组织中的抗 TNF 水平不足以中和局部 TNF 的产生。

相似文献

1
The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study.组织抗 TNF 药物水平与炎症性肠病的血清学和内镜疾病活动的相关性:ATLAS 研究。
Gut. 2016 Feb;65(2):249-55. doi: 10.1136/gutjnl-2014-308099. Epub 2015 Feb 10.
2
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.优化抗TNF-α治疗:英夫利昔单抗和阿达木单抗的血清水平与炎症性肠病患者的黏膜愈合相关。
Clin Gastroenterol Hepatol. 2016 Apr;14(4):550-557.e2. doi: 10.1016/j.cgh.2015.10.025. Epub 2015 Oct 29.
3
Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.炎症性肠病患者中与抗TNF-α谷浓度及抗药物抗体相关的临床和实验室指标
Medicine (Baltimore). 2020 Mar;99(10):e19359. doi: 10.1097/MD.0000000000019359.
4
Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.在维持治疗下缓解期炎症性肠病患者的血清抗 TNF 抗体浓度、不良反应和生活质量。
J Crohns Colitis. 2015 Nov;9(11):973-81. doi: 10.1093/ecco-jcc/jjv116. Epub 2015 Jun 26.
5
Persistence of endoscopic rectal inflammation in UC treated with infliximab is not linked to ineffective TNFα downregulation.接受英夫利昔单抗治疗的溃疡性结肠炎患者内镜下直肠炎症持续存在与肿瘤坏死因子α(TNFα)下调无效无关。
Gut. 2016 Mar;65(3):539-40. doi: 10.1136/gutjnl-2015-310284. Epub 2015 Jul 24.
6
IBD: Tracking TNF and anti-TNF agents in inflamed gut tissue.炎症性肠病:追踪炎症肠道组织中的肿瘤坏死因子及抗肿瘤坏死因子药物
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):189. doi: 10.1038/nrgastro.2015.33. Epub 2015 Feb 24.
7
Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.阿达木单抗药代动力学与炎症性肠病患者黏膜愈合的关系。
Clin Gastroenterol Hepatol. 2014 Jan;12(1):80-84.e2. doi: 10.1016/j.cgh.2013.07.010. Epub 2013 Jul 23.
8
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.阿达木单抗和英夫利昔单抗在母亲和新生儿中的浓度,以及对感染的影响。
Gastroenterology. 2016 Jul;151(1):110-9. doi: 10.1053/j.gastro.2016.04.002. Epub 2016 Apr 8.
9
Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.炎症性肠病患者中英夫利昔单抗和阿达木单抗的血清-肠道动力学差异。
J Crohns Colitis. 2022 Jul 14;16(6):884-892. doi: 10.1093/ecco-jcc/jjab208.
10
Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.药物和抗体的水平与英夫利昔单抗或阿达木单抗治疗应答失败后的干预效果相关。
Clin Gastroenterol Hepatol. 2015 Mar;13(3):522-530.e2. doi: 10.1016/j.cgh.2014.07.029. Epub 2014 Jul 25.

引用本文的文献

1
Acute Severe Ulcerative Colitis in the Modern Era Spotlight on Opioids, Small Molecule Therapy, and Interdisciplinary Communication.现代急性重症溃疡性结肠炎:聚焦阿片类药物、小分子疗法及多学科交流
Dig Dis Sci. 2025 Apr 2. doi: 10.1007/s10620-025-08947-7.
2
Intestinal tissue levels of anti-TNF alpha, antibodies, and cytokines in paediatric Crohn disease.儿童克罗恩病中肠道组织的抗TNFα、抗体及细胞因子水平
Sci Rep. 2025 Jan 7;15(1):1138. doi: 10.1038/s41598-024-83858-7.
3
The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases.
生物和小分子疗法的组织浓度在炎症性肠病临床研究中的应用
Pharmaceutics. 2024 Nov 22;16(12):1497. doi: 10.3390/pharmaceutics16121497.
4
Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients.中度至重度克罗恩病患者血清乌司奴单抗浓度与内镜疾病活动度之间的关联
Crohns Colitis 360. 2024 Nov 29;6(4):otae071. doi: 10.1093/crocol/otae071. eCollection 2024 Oct.
5
Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research.急性重症溃疡性结肠炎的预后预测:当代综述与未来研究方向
J Clin Med. 2024 Aug 1;13(15):4509. doi: 10.3390/jcm13154509.
6
What to do when traditional rescue therapies fail in acute severe ulcerative colitis.急性重症溃疡性结肠炎传统抢救疗法失败时该怎么办。
Intest Res. 2024 Oct;22(4):397-413. doi: 10.5217/ir.2024.00003. Epub 2024 May 16.
7
Case Report: Medical Management of Acute Severe Ulcerative Colitis.病例报告:急性重症溃疡性结肠炎的药物治疗
Gastroenterol Hepatol (N Y). 2023 Oct;19(10):621-627.
8
Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing.优特克单抗治疗抗肿瘤坏死因子难治性小儿溃疡性结肠炎:实现内镜愈合的一种有前景的方法。
Intest Res. 2024 Jul;22(3):351-356. doi: 10.5217/ir.2023.00091. Epub 2024 Feb 6.
9
Unresolved challenges in acute severe ulcerative colitis.急性重症溃疡性结肠炎中未解决的挑战。
Indian J Gastroenterol. 2024 Feb;43(1):9-14. doi: 10.1007/s12664-023-01503-z.
10
A personalized network framework reveals predictive axis of anti-TNF response across diseases.个性化网络框架揭示了跨疾病的抗 TNF 反应的预测轴。
Cell Rep Med. 2024 Jan 16;5(1):101300. doi: 10.1016/j.xcrm.2023.101300. Epub 2023 Dec 19.